157 related articles for article (PubMed ID: 9406245)
1. Bioreductive agents: a clinical update.
Boyer MJ
Oncol Res; 1997; 9(6-7):391-5. PubMed ID: 9406245
[TBL] [Abstract][Full Text] [Related]
2. The effect of functional groups on reduction and activation of quinone bioreductive agents by DT-diaphorase.
Fourie J; Oleschuk CJ; Guziec F; Guziec L; Fiterman DJ; Monterrosa C; Begleiter A
Cancer Chemother Pharmacol; 2002 Feb; 49(2):101-10. PubMed ID: 11862423
[TBL] [Abstract][Full Text] [Related]
3. Clinical studies with EO9, a new indoloquinone bioreductive alkylating cytotoxic agent. EORTC Early Clinical Trials Group.
Verweij J; Aamdal S; Schellens J; Koier I; Lund B
Oncol Res; 1994; 6(10-11):519-23. PubMed ID: 7620220
[TBL] [Abstract][Full Text] [Related]
4. Induction of DT-diaphorase by 1,2-dithiole-3-thione and increase of antitumour activity of bioreductive agents.
Begleiter A; Leith MK; Curphey TJ
Br J Cancer Suppl; 1996 Jul; 27():S9-14. PubMed ID: 8763837
[TBL] [Abstract][Full Text] [Related]
5. The experimental development of bioreductive drugs and their role in cancer therapy.
Workman P; Stratford IJ
Cancer Metastasis Rev; 1993 Jun; 12(2):73-82. PubMed ID: 8375022
[TBL] [Abstract][Full Text] [Related]
6. Enzymology of bioreductive drug activation.
Ross D; Beall HD; Siegel D; Traver RD; Gustafson DL
Br J Cancer Suppl; 1996 Jul; 27():S1-8. PubMed ID: 8763836
[No Abstract] [Full Text] [Related]
7. Bioreductive drugs as post-irradiation sensitizers: comparison of dual function agents with SR 4233 and the mitomycin C analogue EO9.
Adams GE; Stratford IJ; Edwards HS; Bremner JC; Cole S
Int J Radiat Oncol Biol Phys; 1992; 22(4):717-20. PubMed ID: 1544844
[TBL] [Abstract][Full Text] [Related]
8. Induction of DT-diaphorase in cancer chemoprevention and chemotherapy.
Begleiter A; Leith MK; Curphey TJ; Doherty GP
Oncol Res; 1997; 9(6-7):371-82. PubMed ID: 9406243
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, distribution, and metabolism of the novel bioreductive alkylating indoloquinone EO9 in rodents.
Workman P; Binger M; Kooistra KL
Int J Radiat Oncol Biol Phys; 1992; 22(4):713-6. PubMed ID: 1544843
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of interstitial photodynamic therapy by mitomycin C and EO9 in a mouse tumour model.
Baas P; Michielsen C; Oppelaar H; van Zandwijk N; Stewart FA
Int J Cancer; 1994 Mar; 56(6):880-5. PubMed ID: 8119776
[TBL] [Abstract][Full Text] [Related]
11. Enzyme-directed bioreductive drug development revisited: a commentary on recent progress and future prospects with emphasis on quinone anticancer agents and quinone metabolizing enzymes, particularly DT-diaphorase.
Workman P
Oncol Res; 1994; 6(10-11):461-75. PubMed ID: 7620214
[TBL] [Abstract][Full Text] [Related]
12. EO9: a novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models.
Hendriks HR; Pizao PE; Berger DP; Kooistra KL; Bibby MC; Boven E; Dreef-van der Meulen HC; Henrar RE; Fiebig HH; Double JA
Eur J Cancer; 1993; 29A(6):897-906. PubMed ID: 8484984
[TBL] [Abstract][Full Text] [Related]
13. Phase I pharmacokinetics and limited sampling strategies for the bioreductive alkylating drug EO9. EORTC Early Clinical Trials Group.
McLeod HL; Graham MA; Aamdal S; Setanoians A; Groot Y; Lund B
Eur J Cancer; 1996 Aug; 32A(9):1518-22. PubMed ID: 8911111
[TBL] [Abstract][Full Text] [Related]
14. Mitomycin C: a prototype bioreductive agent.
Sartorelli AC; Hodnick WF; Belcourt MF; Tomasz M; Haffty B; Fischer JJ; Rockwell S
Oncol Res; 1994; 6(10-11):501-8. PubMed ID: 7620218
[TBL] [Abstract][Full Text] [Related]
15. Unusually marked hypoxic sensitization to indoloquinone EO9 and mitomycin C in a human colon-tumour cell line that lacks DT-diaphorase activity.
Plumb JA; Workman P
Int J Cancer; 1994 Jan; 56(1):134-9. PubMed ID: 8262670
[TBL] [Abstract][Full Text] [Related]
16. Relative importance of DT-diaphorase and hypoxia in the bioactivation of EO9 by human lung tumor cell lines.
Plumb JA; Gerritsen M; Milroy R; Thomson P; Workman P
Int J Radiat Oncol Biol Phys; 1994 May; 29(2):295-9. PubMed ID: 8195022
[TBL] [Abstract][Full Text] [Related]
17. Oncogenic potential of bifunctional bioreductive drugs.
Hei TK; Liu SX; Hall EJ
Br J Cancer Suppl; 1996 Jul; 27():S57-60. PubMed ID: 8763847
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of a novel in vitro assay for assessing drug penetration into avascular regions of tumours.
Phillips RM; Loadman PM; Cronin BP
Br J Cancer; 1998 Jun; 77(12):2112-9. PubMed ID: 9649122
[TBL] [Abstract][Full Text] [Related]
19. Predicting tumor responses to mitomycin C on the basis of DT-diaphorase activity or drug metabolism by tumor homogenates: implications for enzyme-directed bioreductive drug development.
Phillips RM; Burger AM; Loadman PM; Jarrett CM; Swaine DJ; Fiebig HH
Cancer Res; 2000 Nov; 60(22):6384-90. PubMed ID: 11103802
[TBL] [Abstract][Full Text] [Related]
20. Physiologic and cytotoxic effects of tirapazamine in tumor-bearing mice.
Durand RE; Olive PL
Radiat Oncol Investig; 1997; 5(5):213-9. PubMed ID: 9372543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]